cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)

发表于2024年9月1日由Whatman官网

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc);

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) 通过阻断 GRTH/DDX25 磷酸化，为开发非激素性男性避孕药提供了途径。

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) Chemical Structure

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

生物活性	cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) provides an avenue for developing a nonhormonal male contraceptive by blocking of GRTH/DDX25 phosphorylation.
分子量	946.07
Formula	C₄₀H₆₇N₁₇O₁₀
Sequence Shortening	cyclo(FAGRRRG-{AEEAc})
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Raju M, et al. Blockade of GRTH/DDX25 Phosphorylation by Cyclic Peptides Provides an Avenue for Developing a Nonhormonal Male Contraceptive. J Med Chem. 2021 Oct 14;64(19):14715-14727.

TAT-cyclo-CLLFVY TFA

发表于2024年8月8日由Whatman官网

TAT-cyclo-CLLFVY TFA;

TAT-cyclo-CLLFVY TFA 是一种 HIF-1 异二聚化的环肽抑制剂，可抑制癌细胞中的缺氧信号传导。TAT-cyclo-CLLFVY TFA 破坏 HIF-1α/HIF-1β 蛋白相互作用，IC₅₀ 为 1.3 μM。

TAT-cyclo-CLLFVY TFA Chemical Structure

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

TAT-cyclo-CLLFVY TFA 的其他形式现货产品:

TAT-cyclo-CLLFVY

生物活性

TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM^[1].

体外研究
(In Vitro)

TAT-cyclo-CLLFVY inhibits HIF-1 activity in a mammalian cell luciferase reporter assay^[1].
Hypoxia (1% O2) results in a ~12-fold increase in the luciferase signal, which is inhibited in a dose-dependent manner by TAT-cyclo-CLLFVY (IC₅₀ of 19±2 μM)^[1].
To assess the cell-specificity of TAT-cyclo-CLLFVY, the experiment is repeated in MCF-7 breast cancer cells with similar results (TAT-cyclo-CLLFVY IC₅₀ of 16±1 μM)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

2673.10

Formula

C₁₁₃H₁₈₉F₃N₄₂O₂₆S₂

Sequence Shortening

CGRKKRRQRRRPPQ.cyclo(CLLFVY) (Disulfide bridge:Cys1-Cys1′)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility

In Vitro:;

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

;	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3.;;Recommended solution:

Overall charge of peptide	Details
Negative (lt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH₄OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. Elena Miranda, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013 Jul 17;135(28):10418-25.

Cyclo(RGDyK)

发表于2024年7月21日由Whatman官网

Cyclo(RGDyK);

Cyclo(RGDyK) 是一种有效的选择性 α_Vβ₃ 整联蛋白 (integrin) 抑制剂，IC₅₀ 为 20 nM。

Cyclo(RGDyK) Chemical Structure

CAS No. : 217099-14-4

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

Cyclo(RGDyK) 的其他形式现货产品:

Cyclo(RGDyK) trifluoroacetate

生物活性	Cyclo(RGDyK) is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.
IC₅₀ Target	IC50: 20 nM (α_Vβ₃ Integrin), 3000 nM (α_IIbβ₃ Integrin), 4000 nM (α_Vβ₅ Integrin)^[1]
体外研究 (In Vitro)	Cyclo(RGDyK) (c(RGDyK(SAA)) shows high affinity and selectivity for α_Vβ₃ over α_Vβ₅ (IC₅₀=4000 nM) and α_IIbβ₃ (IC₅₀=3000 nM)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	619.67
Formula	C₂₇H₄₁N₉O₈
CAS 号	217099-14-4
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Haubner R, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001 Feb;42(2):326-36.

Cyclo(Gly-Gln)

发表于2024年7月18日由Whatman官网

Cyclo(Gly-Gln);

Cyclo(Gly-Gln) 是一种环状二肽。

Cyclo(Gly-Gln) Chemical Structure

CAS No. : 52662-00-7

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

生物活性

Cyclo(Gly-Gln) is a cyclic dipeptide^[1].

分子量

185.18

Formula

C₇H₁₁N₃O₃

CAS 号

52662-00-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility

In Vitro:;

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

;	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3.;;Recommended solution:

Overall charge of peptide	Details
Negative (lt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH₄OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. Takashi Mizuma, et al. Uptake of Cyclic Dipeptide by PEPT1 in Caco-2 Cells: Phenolic Hydroxyl Group of Substrate Enhances Affinity for PEPT1. J Pharm Pharmacol. 2002 Sep;54(9):1293-6.

Cyclo(Tyr-Leu)

发表于2024年7月14日由Whatman官网

Cyclo(Tyr-Leu);

Cyclo(Tyr-Leu) 是一种环状二肽。

Cyclo(Tyr-Leu) Chemical Structure

CAS No. : 82863-65-8

规格	价格	是否有货	数量
5 mg	￥1800	In-stock
10 mg	￥2800	In-stock
25 mg	￥5600	In-stock
50 mg	￥8900	In-stock
100 mg	￥13500	In-stock
200 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

生物活性

Cyclo(Tyr-Leu) is a cyclic dipeptide^[1].

分子量

276.33

Formula

C₁₅H₂₀N₂O₃

CAS 号

82863-65-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-80deg;C	2 years
	-20deg;C	1 year
In solvent	-80deg;C	6 months
	-20deg;C	1 month

Solvent Solubility

In Vitro:;

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

;	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3.;;Recommended solution:

Overall charge of peptide	Details
Negative (lt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH₄OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. Takashi Mizuma, et al. Uptake of Cyclic Dipeptide by PEPT1 in Caco-2 Cells: Phenolic Hydroxyl Group of Substrate Enhances Affinity for PEPT1. J Pharm Pharmacol. 2002 Sep;54(9):1293-6.

Cyclo(Gly-Tyr)

发表于2024年7月2日由Whatman官网

Cyclo(Gly-Tyr);

Cyclo(Gly-Tyr) 是一种环状二肽。

Cyclo(Gly-Tyr) Chemical Structure

CAS No. : 5845-66-9

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

生物活性

Cyclo(Gly-Tyr) is a cyclic dipeptide^[1].

分子量

220.22

Formula

C₁₁H₁₂N₂O₃

CAS 号

5845-66-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility

In Vitro:;

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

;	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3.;;Recommended solution:

Overall charge of peptide	Details
Negative (lt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH₄OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. Takashi Mizuma, et al. Uptake of Cyclic Dipeptide by PEPT1 in Caco-2 Cells: Phenolic Hydroxyl Group of Substrate Enhances Affinity for PEPT1. J Pharm Pharmacol. 2002 Sep;54(9):1293-6.

Cyclo(-RGDfK)

发表于2024年5月9日由Whatman官网

Cyclo(-RGDfK); 纯度: ge;98.0%

Cyclo(-RGDfK) 是有效，选择性的整合素 α_vβ₃ 抑制剂，其 IC₅₀ 值为 0.94 nM。Cyclo(-RGDfK) TFA 通过与细胞表面的 αvβ3 整合素结合，特异性靶向肿瘤微血管和癌细胞。

Cyclo(-RGDfK) Chemical Structure

CAS No. : 161552-03-0

规格	价格	是否有货	数量
10;mM;*;1 mL in DMSO	￥1541	In-stock
5 mg	￥1160	In-stock
10 mg	￥1800	In-stock
50 mg	￥6500	In-stock
100 mg	￥7500	In-stock
200 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

Cyclo(-RGDfK) 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Peptidomimetic Library
Macrocyclic Compound Library
Cytoskeleton Compound Library
Peptide Library

生物活性

Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM^[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface^[2].

IC₅₀ Target

IC50: 0.94 nM (α_vβ₃ integrin)^[1].

体外研究
(In Vitro)

Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with a IC₅₀ of 0.94 nM^[1]. [⁶⁶Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting α_vβ₃-targeted tracer accumulation^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

603.67

Formula

C₂₇H₄₁N₉O₇

CAS 号

161552-03-0

Sequence Shortening

Cyclo(RGDFK)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-80deg;C	2 years
	-20deg;C	1 year
In solvent	-80deg;C	6 months
	-20deg;C	1 month

溶解性数据

In Vitro:;

DMSO : 125 mg/mL (207.07 mM; Need ultrasonic)

H₂O : 50 mg/mL (82.83 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6565 mL	8.2827 mL	16.5653 mL
5 mM	0.3313 mL	1.6565 mL	3.3131 mL
10 mM	0.1657 mL	0.8283 mL	1.6565 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

Solubility: ≥ 2.08 mg/mL (3.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.45 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (3.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.45 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.45 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

参考文献

[1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.

[2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.

Cyclo(Phe-Pro)(Synonyms: Cyclo(phenylalanylprolyl) A-64863)

发表于2024年5月2日由Whatman官网

Cyclo(Phe-Pro);(Synonyms: Cyclo(phenylalanylprolyl); A-64863) 纯度: 98.06%

Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) 是一种创伤弧菌的群体感应分子，通过与 RIG-I 的特异性相互作用，抑制 RIG-I 的多泛素化，并抑制 IRF-3 的激活和 I 型干扰素的产生。Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) 增强 HCV 和流感病毒的易感性。

Cyclo(Phe-Pro)amp;;(Synonyms: Cyclo(phenylalanylprolyl); A-64863)

Cyclo(Phe-Pro) Chemical Structure

CAS No. : 14705-60-3

规格	价格	是否有货	数量
5 mg	￥500	In-stock
10 mg	￥800	In-stock
50 mg	￥2400	In-stock
100 mg	￥3800	In-stock
200 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

Cyclo(Phe-Pro) 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Peptide Library

生物活性

Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses^[1].

分子量

244.29

Formula

C₁₄H₁₆N₂O₂

CAS 号

14705-60-3

Sequence Shortening

Cyclo(FP)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light

Powder	-80deg;C	2 years
	-20deg;C	1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light)

溶解性数据

In Vitro:;

DMSO : 125 mg/mL (511.69 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0935 mL	20.4675 mL	40.9350 mL
5 mM	0.8187 mL	4.0935 mL	8.1870 mL
10 mM	0.4093 mL	2.0467 mL	4.0935 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.51 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.51 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.51 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

参考文献

[1]. Lee W, et al. Vibrio vulnificus quorum-sensing molecule cyclo(Phe-Pro) inhibits RIG-I-mediated antiviral innate immunity. Nat Commun. 2018 Apr 23;9(1):1606.

TAT-cyclo-CLLFVY

发表于2024年4月20日由Whatman官网

TAT-cyclo-CLLFVY; 纯度: 99.09%

TAT-cyclo-CLLFVY 是一种 HIF-1 异二聚化的环肽抑制剂，可抑制癌细胞中的缺氧信号传导。TAT-cyclo-CLLFVY 破坏 HIF-1α/HIF-1β 蛋白相互作用，IC₅₀ 为 1.3 μM。

TAT-cyclo-CLLFVY Chemical Structure

CAS No. : 1446322-66-2

规格	价格	是否有货	数量
1 mg	￥2100	In-stock
5 mg	￥7400	In-stock
10 mg	￥11800	In-stock
50 mg	;	询价	;
100 mg	;	询价	;

* Please select Quantity before adding items.

TAT-cyclo-CLLFVY 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Peptide Library

生物活性

TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM^[1].

体外研究
(In Vitro)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

2559.08

Formula

C₁₁₁H₁₈₈N₄₂O₂₄S₂

CAS 号

1446322-66-2

Sequence Shortening

CGRKKRRQRRRPPQ.cyclo(CLLFVY) (Disulfide bridge:Cys1-Cys1′)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-80deg;C	2 years
	-20deg;C	1 year
In solvent	-80deg;C	6 months
	-20deg;C	1 month

溶解性数据

In Vitro:;

DMSO : 50 mg/mL (19.54 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.3908 mL	1.9538 mL	3.9077 mL
5 mM	0.0782 mL	0.3908 mL	0.7815 mL
10 mM	0.0391 mL	0.1954 mL	0.3908 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

Solubility: ≥ 2.5 mg/mL (0.98 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (0.98 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (0.98 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (0.98 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

Solubility: ≥ 2.5 mg/mL (0.98 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (0.98 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

参考文献

[1]. Elena Miranda, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013 Jul 17;135(28):10418-25.

Cyclo(-RGDfK) TFA

发表于2024年4月15日由Whatman官网

Cyclo(-RGDfK) TFA; 纯度: 99.81%

Cyclo(-RGDfK) TFA 是有效，选择性的整合素 α_vβ₃ 抑制剂，其 IC₅₀ 值为 0.94 nM。Cyclo(-RGDfK) TFA 通过与细胞表面的 αvβ3 整合素结合，特异性靶向肿瘤微血管和癌细胞。

Cyclo(-RGDfK) TFA Chemical Structure

CAS No. : 500577-51-5

规格	价格	是否有货	数量
10;mM;*;1 mL in DMSO	￥2190	In-stock
5 mg	￥1160	In-stock
10 mg	￥1800	In-stock
50 mg	￥6500	In-stock
100 mg	;	询价	;
200 mg	;	询价	;

* Please select Quantity before adding items.

Cyclo(-RGDfK) TFA 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Macrocyclic Compound Library
Cytoskeleton Compound Library
Peptide Library

生物活性

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM^[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface^[3].

IC₅₀ Target

IC50: 0.94 nM (α_vβ₃ integrin)^[1]

体外研究
(In Vitro)

Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin and exhibits a IC₅₀ of 0.94 nM^[1].
[⁶⁶Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting α_vβ₃-targeted tracer accumulation^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

717.69

Formula

C₂₉H₄₂F₃N₉O₉

CAS 号

500577-51-5

Sequence Shortening

Cyclo(RGDFK)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80deg;C	2 years
	-20deg;C	1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:;

DMSO : 100 mg/mL (139.34 mM; Need ultrasonic)

H₂O : 33.33 mg/mL (46.44 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3934 mL	6.9668 mL	13.9336 mL
5 mM	0.2787 mL	1.3934 mL	2.7867 mL
10 mM	0.1393 mL	0.6967 mL	1.3934 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂：;PBS

Solubility: 130 mg/mL (181.14 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

Solubility: ≥ 2.08 mg/mL (2.90 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.90 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (2.90 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.90 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

Solubility: ≥ 2.08 mg/mL (2.90 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.90 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

参考文献

[1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.

[2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.

Cytiva思拓凡-Whatman滤纸滤膜滤器

沃特曼官网代理商|Whatman滤纸滤膜中国官网代理商

标签归档：cyclo

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)

TAT-cyclo-CLLFVY TFA

Cyclo(RGDyK)

Cyclo(Gly-Gln)

Cyclo(Tyr-Leu)

Cyclo(Gly-Tyr)

Cyclo(-RGDfK)

Cyclo(-RGDfK) 相关产品

bull;相关化合物库:

Cyclo(Phe-Pro)(Synonyms: Cyclo(phenylalanylprolyl) A-64863)

Cyclo(Phe-Pro) 相关产品

bull;相关化合物库:

TAT-cyclo-CLLFVY

TAT-cyclo-CLLFVY 相关产品

bull;相关化合物库:

Cyclo(-RGDfK) TFA

Cyclo(-RGDfK) TFA 相关产品

bull;相关化合物库: